PDF

Keywords

antigen specific therapy

،
؛bioactive proteins
؛immune tolerance
؛Lactococcus lactis
؛type-1 diabetes

Abstract

Globally, type 1 diabetes mellitus is a common chronic autoimmune disease impacts a great number of individuals. It results from devastation of insulin-secreting beta cells of the pancreas described by incompetence to secrete insulin resulting in hyperglycemia that need a ceaseless treatment with insulin. Further, complications of type 1 diabetes can influence numerous organs and may prompt premature death. Therefore, the requirement to find new strategies for managing type 1 diabetes other than exogenous insulin administration got obligatory. Curiously, genetically modified Lactococcus lactis can incite immunological tolerance; downregulate mechanisms linked to adaptive immunity; and reduce disease-related inflammation, while leaving the remainder of the immune system flawless. This review aimed to overview genetically modified Lactococcus lactis, it's expressing proteins, pathogenesis of type 1diabetes, and therapeutic effects of genetically modified Lactococcus lactis in animal model of type 1daibetes, further, to display the possible mechanisms through which the genetically modified Lactococcus lactis can act. It has been presumed that targeting antigen-specific pathway utilizing genetically modified Lactococcus lactis has potential therapeutic impacts in experimental animals with type 1 diabetes mellitus. This could open up new and safe therapeutic prospects in autoimmune disease domain such as type 1diabetes mellitus.
https://doi.org/10.33899/mmed.2020.127468.1040
  PDF